Pharma Manufactures Charged With Conspiracy

Texas Attorney General Ken Paxton has launched a high-profile lawsuit against leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of conspiring to inflate insulin prices in a scheme that has left diabetic patients across the state struggling to afford their medication.

Pharmacy benefit managers act as middlemen between drug manufacturers and pharmacies, negotiating prices and determining which medications are covered by insurance plans. But Paxton alleges these intermediaries have been part of a troubling conspiracy with drug manufacturers to rig insulin pricing, in violation of Texas law.

According to the lawsuit, insulin manufacturers have increased the price of their life-saving drugs by up to 1,000%. Paxton claims this was done through a kickback system, where manufacturers paid undisclosed rebates to PBMs to secure a coveted spot on their preferred drug lists. This practice, he asserts, has created an incentive to hike prices rather than control them, further burdening patients already grappling with the high costs of diabetes management.

“This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin,” Paxton said in a statement. “Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could.”

He added: “These companies acted illegally and unethically to enrich themselves, and we will hold them accountable.”

A State Taking on Big Pharma

The lawsuit names several pharmaceutical giants and PBMs as defendants, including CVS Pharmacy, Eli Lilly, and Express Scripts. It seeks a range of remedies, including injunctive relief to stop the alleged practices, compensation for damages suffered by Texans, disgorgement of illegal profits, civil penalties, and reimbursement for legal fees.

The stakes are high. Texas has one of the highest diabetes rates in the nation, with over 2.8 million adults diagnosed, according to the Texas Department of State Health Services. The cost of insulin has become a flashpoint in recent years, with studies showing prices tripling over the past decade. For many, these skyrocketing costs have meant rationing medication or foregoing it entirely—choices that can have deadly consequences.

Insulin, discovered over a century ago, remains essential for millions of diabetics, but its cost has risen dramatically despite no significant changes to the formula. Critics say this reflects broader issues in the pharmaceutical industry, where profits often seem prioritized over patients.

A National Trend?

Paxton’s lawsuit could set a precedent for other states to follow, especially as calls for accountability in the pharmaceutical sector grow louder. Some states have already begun addressing insulin prices through legislation or price caps, but Texas’ approach is a bold example of direct legal action against both manufacturers and intermediaries.

As the case unfolds, it could bring to light practices that critics argue have long plagued the healthcare system. Paxton’s move also underscores a growing belief among conservative leaders that decisive state action is necessary to combat corporate overreach.

“Market reforms alone are no longer enough,” Paxton said. “States must take the lead in protecting their citizens from the predatory practices of Big Pharma.”

The battle lines are drawn. Texas is not just challenging corporate greed—it’s sending a message to the rest of the nation: business as usual in the pharmaceutical industry won’t be tolerated.